<qa>  What is SF1126 a novel inhibitor of?SF1126 is a novel inhibitor of PI3 kinase and mTOR that includes an active moiety consisting of LY294002 linked to an RGDS tetrapeptide that targets the active agent to integrin expressing tissues. In this first pediatric phase 1 trial of SF1126, dose escalation will follow a 33 dose escalation design. Once a recommended phase 2 pediatric dose is identified, an expansion cohort of 10 patients with tumors with MYCN amplification, Mycn expression, or Myc expression will be treated. 